HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OPCH
Option Care Health, Inc.
OPCH's fundamentals are mixed: free cash flow grew 28%, while its operating margin held steady at 5.9%. At 23x earnings, it's trading below its usual 26x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OPCH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
OPCH's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OPCH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $31.68 | — |
| Cheap | 20x | $27.79 | -12% |
| Current | 23x | $31.68 | — |
| Fair | 26x | $36.15 | +14% |
| Expensive | 38x | $52.50 | +66% |
Historical ranges are pointers, not guarantees.
OPCH's PE is in its cheap range at 23x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OPCH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
OPCH has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
OPCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.02 | +47% |
| Q3 2026 | $1.38 | +8.7% |
| Q2 2026 | $1.32 | +4.8% |
| Q1 2026 | $1.28 | +2.4% |
| Q4 2025 | $1.27 | +3.3% |
| Q3 2025 | $1.27 | +5.8% |
| Q2 2025 | $1.26 | +5% |
| Q1 2025 | $1.25 | -18% |
| Q4 2024 | $1.23 | -17% |
OPCH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OPCH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
OPCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +4.1% |
| Q2 2026 | $1.4B | +1.9% |
| Q1 2026 | $1.4B | +1.3% |
| Q4 2025 | $1.5B | +16% |
| Q3 2025 | $1.4B | +12% |
| Q2 2025 | $1.4B | +15% |
| Q1 2025 | $1.3B | +16% |
| Q4 2024 | $1.3B | +12% |
OPCH's revenue has grown year over year every quarter since late 2020: $1.5B last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6% | +0.1 points |
| Q2 2026 | 5.9% | +0.1 points |
| Q1 2026 | 5.4% | -0.6 points |
| Q4 2025 | 6.2% | -0.7 points |
| Q3 2025 | 5.9% | -0.8 points |
| Q2 2025 | 5.8% | -0.7 points |
| Q1 2025 | 5.9% | -0.1 points |
| Q4 2024 | 6.9% | -0.6 points |
OPCH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OPCH on cash flow, with more consistent year-over-year improvement.
OPCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $108M | -17% |
| Q2 2026 | $172.5M | +112% |
| Q1 2026 | -$21.2M | -$4.6M |
| Q4 2025 | $22.2M | -14% |
| Q3 2025 | $130.2M | -14% |
| Q2 2025 | $81.2M | -56% |
| Q1 2025 | -$16.6M | +$58M |
| Q4 2024 | $25.8M | -17% |
OPCH generated $282M in free cash flow over the past year, up 28% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OPCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -3M shares |
| 1 year | -7.7% | -12.6M shares |
| 3 years | -17% | -30M shares |
| 5 years | -17% | -30.9M shares |
| Available history | -3.7% | -5.8M shares |
OPCH has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | $95.1M |
| Q3 2025 | $62.5M |
| Q4 2024 | $92.6M |
| Q3 2024 | $42M |
| Q2 2024 | $78.1M |
| Q1 2024 | $40.1M |
| Q4 2023 | $75.2M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OPCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.3x | Moderate |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 1.8x | Healthy |
OPCH's net debt is about 2.1 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OPCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.8 | Neutral |
| Stochastic | 98.1 | Overbought |
OPCH's weekly RSI is 70 (neutral) and its Stochastic is 98 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OPCH PE vs Healthcare Sector
| Metric | OPCH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 32 | 29 | 3 pts above |
OPCH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OPCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.3 | 8.2% above |
| 20 week MA | $25.6 | 24% above |
| 50 week MA | $27.3 | 16% above |
| 100 week MA | $28.6 | 11% above |
| 200 week MA | $29.5 | 7.2% above |
OPCH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
OPCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $15.6 | +5.1% |
| 2021 | $15.6 | $28.0 | +80% |
| 2022 | $28.0 | $30.2 | +8.1% |
| 2023 | $30.2 | $33.7 | +11% |
| 2024 | $33.7 | $22.9 | -32% |
| 2025 | $22.9 | $32.6 | +43% |
| 2026 YTD | $32.6 | $31.7 | -2.8% |
OPCH has the edge over HIMS on returns for 2026, with the stronger performance.